China Inhalation Preparation Market Insight Report 2021-2025 – ResearchAndMarkets.com

China Inhalation Preparation Market Insight Report 2021-2025 – ResearchAndMarkets.com




China Inhalation Preparation Market Insight Report 2021-2025 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “China Inhalation Preparation Market Insight Report, 2021-2025” report has been added to ResearchAndMarkets.com’s offering.

In 2019, the global market size of asthma /COPD drug market exceeded USD 20 billion, and China’s market size was about RMB 20 billion. Inhalation preparation, as the preferred mode of administration, has clear mechanism of action and numerous pharmaceutical dosage forms.

The basic therapeutic drugs are glucocorticoid and bronchodilator, and the dosage forms are divided into aerosol, powder mist, atomized inhalation and spray.

The drug structure in China and the world is different. In terms of formula, LABA+ICS compound preparation is the main drug market in the world, and ICS unilateral preparation is the main drug in China.

In terms of dosage forms, powder aerosol and aerosol account for nearly 80% of the total in the global market, while atomized inhalants account for 73% in the Chinese market. It is worth noting that the localization rate of inhalant preparations in China is less than 10%.

Because the policy environment and market educators in China are different from those in overseas countries, the game rules and marketing strategies of enterprises are different. At present, the drug use structure is mostly the result of the business strategies of market educators.

In the future, China’s inhalation preparation market is expected:

  • The scale of compound preparations will increase
  • Atomization will still dominate in the short to medium term, and aerosol agents will rise
  • The evaluation policy is clear now, and the industrial development will accelerate.

Key Topics Covered:

1. Respiratory diseases are frequent, and asthma and COPD are the main diseases

1.1. Respiratory diseases are high, and the mortality rate ranks among the top five in China

1.2. Asthma and COPD are the main chronic respiratory diseases, with a large base and low diagnostic rate in China

1.3. Asthma and COPD are two kinds of diseases with different diagnosis and treatment methods

2. Inhalation preparation is the preferred method of administration, and the localization rate is less than 10%

2.1. The global market for asthma /COPD is 100 billion, and the market in China is 10 billion

2.2. The drug mechanism of inhalation preparation is clear, mainly ICS and bronchodilator

2.3. There are about four dosage forms of inhalation preparations, and the atomization solution is the main market in China

2.4. It is extremely difficult to imitate inhaled preparations, and the localization rate in China is less than 10%

2.4.1. Medicine and equipment are integrated, and research and development barriers are extremely high

2.4.2. The original research patents are strict, and it is difficult to see the “patent cliff”

2.4.3. the be standard has been unclear for many years

3. The Chinese market is different from overseas, paying attention to the business strategy of market educators

3.1. Sources of Chinese characteristics: Different policy environments and different market leaders

3.2. The essence of product pattern: the business strategy of market educators

3.2.1. Why can budesonide suspension dominate the Chinese market?

3.2.2. Is Seretide the best compound preparation of GSK?

3.2.3. Why is Seretide, the best-selling in the world, not as big as Reliance in China?

3.2.4. Why is the localization rate of tiotropium bromide powder mist agent close to 50%?

3.3. Development of inhalant preparations in China: Three major trends of industrial upgrading

3.3.1. Trend 1: The scale of compound preparation is expected to increase

3.3.2. Trend 2: Atomization is given priority and powder mist agent needs to rise

3.3.3. Trend 3: The BE policy is now clear, and the industrial development will be accelerated

4. Depth analysis of domestic peers

5. Appendix

5.1. Appendix I: Differences between asthma and COPD in disease characteristics

5.2. Appendix II: Classification of Commonly Used Drugs for Asthma and COPD

5.3. Appendix III: TOP10 drugs for inhalation preparations in sample hospitals in China

5.4. Appendix IV: Guiding Principles of Inhalation Preparation BE in China

5.5. Appendix V: Key products of inhalation preparations in China have been approved and are being researched and combed

Companies Mentioned

  • Joincare Pharmaceutical Group Industry Co., Ltd.
  • Jiangsu Hengrui Medicine Co.,Ltd.
  • Sino Biopharmaceutical Limited.
  • Zhejiang Xianju Pharmaceutical Co.,Ltd.
  • CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
  • CF PharmTech, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/rjtrow

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900